Chinese clinical stage biotechnology company Shanghai Yingli Pharmaceutical Co Ltd (Yingli Pharma) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) to initiate a global registration Phase 3 study of linperlisib versus physicians' choice of standard of care, for the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
This approval follows a successful Type B End-of-Phase 2 meeting, during which the company discussed the overall development program and regulatory path.
Yingli Pharma expects the Phase 3 study to commence during the second quarter of 2025.
Linperlisib is a potent oral small molecule inhibitor of the delta isoform of PI3 kinase (PI3K delta) developed by Yingli Pharma.
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
Organon acquires US rights to TOFIDENCE from Biogen
Oncopeptides secures FDA approval to resume OPD5 clinical development
Bonesupport submits FDA application for CERAMENT V
Spinogenix starts enrolment for SPG302 Phase 2 trial in schizophrenia
DDL opens new GMP laboratory for drug-device combination product testing
Langhua Pharmaceutical passes US FDA's on-site inspection
PTC Therapeutics announces opinion regarding Translarna's (ataluren) European renewal authorisation
Soleno Therapeutics selects PANTHERx Rare as specialty pharmacy for VYKAT XR distribution